Literature DB >> 24061773

Acute myeloid leukemia and colon carcinoma during the course of acromegaly.

Kazutaka Ozeki1, Yoshihisa Morishita, Sigeki Saito, Koji Umemura, Yohei Yamaguchi, Shotaro Tatekawa, Koichi Watamoto, Akio Kohno, Tsuyoshi Nogimori.   

Abstract

We describe the case of a 70-year-old male with acromegaly who developed colon carcinoma and myelodysplastic syndrome (MDS) during the course of acromegaly. MDS progressed to acute myeloid leukemia, but was refractory to chemotherapy. Acromegaly is a rare disorder caused by excessive amounts of growth hormone (GH) primarily secreted by pituitary adenomas. Patients with acromegaly are more prone to develop various malignancies, but there are few reports of hematological malignancies in such patients. In the present case, excessive endogenous GH and insulin-like growth factor-I levels may have altered cell proliferation and thereby affected the oncogenesis and chemosensitivity of both malignancies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24061773     DOI: 10.1007/s12185-013-1431-8

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  27 in total

1.  Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984.

Authors:  B A Bengtsson; S Edén; I Ernest; A Odén; B Sjögren
Journal:  Acta Med Scand       Date:  1988

2.  Benign and malignant tumors in patients with acromegaly.

Authors:  J Barzilay; G J Heatley; G W Cushing
Journal:  Arch Intern Med       Date:  1991-08

3.  IGF signaling contributes to malignant transformation of hematopoietic progenitors by the MLL-AF9 oncoprotein.

Authors:  Christopher R Jenkins; Olena O Shevchuk; Vincenzo Giambra; Sonya H Lam; Joan M Carboni; Marco M Gottardis; Martin Holzenberger; Michael Pollak; R Keith Humphries; Andrew P Weng
Journal:  Exp Hematol       Date:  2012-05-18       Impact factor: 3.084

4.  Recent status in the occurrence of leukemia in growth hormone-treated patients in Japan. GH Treatment Study Committee of the Foundation for Growth Science, Japan.

Authors:  Y Nishi; T Tanaka; K Takano; K Fujieda; Y Igarashi; K Hanew; T Hirano; S Yokoya; K Tachibana; T Saito; S Watanabe
Journal:  J Clin Endocrinol Metab       Date:  1999-06       Impact factor: 5.958

5.  Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: effect of the dual-receptor inhibitor BMS-536924 in vitro.

Authors:  Andrea E Wahner Hendrickson; Paul Haluska; Paula A Schneider; David A Loegering; Kevin L Peterson; Ricardo Attar; B Douglas Smith; Charles Erlichman; Marco Gottardis; Judith E Karp; Joan M Carboni; Scott H Kaufmann
Journal:  Cancer Res       Date:  2009-09-29       Impact factor: 12.701

6.  Chronic myeloid leukemia and acromegaly in POEMS syndrome.

Authors:  P T Murphy; N Ahmed; H T Hassan
Journal:  Leuk Res       Date:  2002-12       Impact factor: 3.156

7.  Possible association of human growth hormone treatment with an occurrence of acute myeloblastic leukemia with an inversion of chromosome 3 in a child of pituitary dwarfism.

Authors:  M Endo; Y Kaneko; T Shikano; H Minami; J Chino
Journal:  Med Pediatr Oncol       Date:  1988

8.  The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion.

Authors:  P L Tazzari; G Tabellini; R Bortul; V Papa; C Evangelisti; T Grafone; G Martinelli; J A McCubrey; A M Martelli
Journal:  Leukemia       Date:  2007-03-15       Impact factor: 11.528

9.  Autocrine insulin-like growth factor-I signaling promotes growth and survival of human acute myeloid leukemia cells via the phosphoinositide 3-kinase/Akt pathway.

Authors:  K T Doepfner; O Spertini; A Arcaro
Journal:  Leukemia       Date:  2007-06-21       Impact factor: 11.528

Review 10.  Remission induction in acute myeloid leukemia.

Authors:  Eytan M Stein; Martin S Tallman
Journal:  Int J Hematol       Date:  2012-07-13       Impact factor: 2.490

View more
  1 in total

1.  Insulin-like growth factor 1 is a direct HOXA9 target important for hematopoietic transformation.

Authors:  J Steger; E Füller; M-P Garcia-Cuellar; K Hetzner; R K Slany
Journal:  Leukemia       Date:  2014-09-25       Impact factor: 11.528

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.